Literature DB >> 8106585

High-performance liquid chromatographic method for the routine determination of diclofenac and its hydroxy and methoxy metabolites from in vitro systems.

G Schmitz1, H Lepper, C J Estler.   

Abstract

A rapid and sensitive high-performance liquid chromatographic method is presented for the determination of diclofenac and its hydroxylated and methoxylated metabolites. The procedure describes extraction of diclofenac and its metabolites from acidified incubation medium into tert.-butylmethyl ether. Separation is achieved with a C18 reversed-phase column and quantification by UV detection at 280 nm. The method employs an internal standard resulting in good accuracy and precision. The limit of detection is 5 ng/ml for diclofenac and 10 ng/ml for its metabolites. One analysis requires no more than twelve minutes so that the assay is very suitable for the determination of a large number of samples.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106585     DOI: 10.1016/0378-4347(93)80065-c

Source DB:  PubMed          Journal:  J Chromatogr


  4 in total

Review 1.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Diclofenac metabolic profile following in vitro percutaneous absorption through viable human skin.

Authors:  H Tanojo; R C Wester; J Z Shainhouse; H I Maibach
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.441

3.  Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity.

Authors:  Praveen Rajendran; Manu Jaggi; Manoj K Singh; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2007-09-13       Impact factor: 3.850

4.  In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.

Authors:  Jacek Wójcikowski; Przemysław J Danek; Agnieszka Basińska-Ziobroń; Renata Pukło; Władysława A Daniel
Journal:  Pharmacol Rep       Date:  2020-03-26       Impact factor: 3.024

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.